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The mechanisms of cells malignant transformation 
and predisposition to breast cancer (BC), ovarian can-
cer (OC) and other organs cancer represent the most ac-
tual oncologic problem. Increased attention to patients 
with BC and OC is based on epidemiological, clinical 
and biological peculiarities of these tumors. BC belongs 
to the most common forms of malignant tumors world-
wide without tendency towards decrease of morbidity, 
and has multiple clinical-biological and variable clini-
cal course [1]. OC refers to the tumors with mysterious 
pathogenesis, with high morbidity and mortality of pa-
tients resulting from late diagnosis in spite of possibil-
ities of ultrasound diagnostics of the pathology in ear-
ly sta ges [2]. These cancer forms are often observed in 
seve ral generations of patients, and sometimes — also 
as primary multiple tumors (PMT) in single person [3]. 
The problem of PMT, both synchronous and meta-
chronous, also refers to important issues that require 
detailed study due to greater life expectancy of popula-
tion, including patients after treatment of female repro-
ductive system organs (FRSO) cancer and colon cancer 
(CC). In PMT pathogenesis genetic predisposition to 
cancer incidence in also important due to genome in-
stability which also may be associated with specific pa-
tients’ treatment, and also with influence of radiogenic, 
chemical factors and others on human body in modern 
conditions of life.
Achievements of genetic and molecular biology ex-
tended knowledge of the nature of cells malignization 
and role of genes in tumor growth [4–8]. Mutation in 
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the genes — suppressors of tumor grown BRCA1 and 
BRCA2 refer to genetic alterations which may facilitate 
tumor development [9–12]. Most clearly the role of gene 
mutations in predisposition to cancer development may 
be followed on the example of family cancer syndrome 
(Lynch syndrome) [13, 14].
Currently, in the mechanisms of predisposition to 
cancer development, including its hereditary variants, 
the attention is paid not only to mutations in the genes 
BRCA1 and BRCA2, but also to the mutations in the genes 
of DNA reparation: CHEK2, ATM, BRIP1 (FANCJ), 
PALB2 (FANCN), RAD51C (FANCO), among which 
the gene CHEK2 was recognized as a gene of multi-or-
ganic predisposition to cancer development [15]. Clin-
ical and molecular-genetic studies in various countries 
determined the role of single nucleotide polymorphism 
(SNP) also as a marker of predisposition to BC and oth-
er forms of patho logy [16–19], although the mechanisms 
of potential malignization of cells with SNP involvement 
need further investigations. In this context, attention is 
drawn to SNP of estrogen receptor gene ERS1 that is 
involved in hormo nal metabolism of normal cells and 
hormonal pathoge nesis of a number of malignant tu-
mors [17], in particular, BC and OC. Mutations of es-
trogen receptor gene ERS1 lead to disorder of estrogen 
signaling and inter-gene interactions, and to alteration 
of hormonal status of cells and tissues. Therefore, in the 
recent years there was a growing number of studies ded-
icated to the role of SNP of ЕRS1 gene. Considering the 
importance of hormonal homeostasis disorders in de-
velopment and progression neoplasms, study of SNP of 
ERS1 is important for determination of genetic risk for 
cancer deve lopment in FRSO.
Clinical studies demonstrated that increased risk of 
cancer development in members of families with tumor 
pathology aggregation really exists, but the issue of what 
exact factors or its complex facilitate neoplasias develop-
ment in proband’s relatives remains unspecified. There-
fore, the priority direction in modern oncology is a search 
for molecular markers which application would contri-
bute to the definition of persons with the highest risk of 
malignization. Knowledge of such markers would form 
a basis for its application in the development of clinical 
protocols of examination of members of families with 
family cancer syndrome.
Aim of the work: to determine genetic risk of oncolo-
gic pathology development in pedigrees of probands from 
families with family cancer history and patients with PMT 
basing on the results of clinical-genealogical examina-
tion and genetic analysis of estrogen receptor gene ESR1 
in patients with OC and BC.
OBJECT AND METHODS
The study enrolled 90 patients with FRSO cancer 
(BC, OC, primary multiple FRSO tumors) from fami-
lies with cancer family history and 55 practically healthy 
females without cancer cases in their pedigrees. All ex-
amined females were Ukrainians and lived in Cherkassy 
region of Ukraine.
All probands (cancer patients and practically healthy 
females) independently completed their clinical-genea-
logical maps that further were analyzed and complemen-
ted by oncologist-gynecologist during personal interview 
with proband and also at reviewing of medical documen-
tation after probands complex examination according to 
examination standards of patients adopted in Ukraine. 
During interview with proband the attention was paid to 
the following data: number of relatives, suffering from 
cancer, of I–III degree of kindship, their family relation-
ship to proband. Clinical-genealogical analysis was im-
plemented according to Amsterdam criteria II (three of 
more relatives with Lynch-associated tumors — colorec-
tal cancer, BC, OC, gastric cancer (GC) and others, at 
that one of oncologic patients should have I degree of 
kindship with other relatives, and malignant tumors — 
at least in two generations). In examined healthy females 
there were no relatives with cancer in three generations of 
family tree. All cancer patients that underwent clinical-
genealogical examination received medical assistance, 
including surgical, complex or combined treatment ac-
cording to the Ukrainian standards of patients’ treat-
ment in CE «Cherkassy Regional Oncologic Dispensa-
ry» (Cherkassy, Ukraine). The stage of tumor process in 
cancer patients was evaluated according to FIGO clas-
sification, tumors verification was carried out by mor-
phologist. All probands gave written consent to appli-
cation of their biological material in scientific research.
Genomic DNA for molecular-genetic study was iso-
lated from histological sections of paraffin blocks of sur-
gical material in 46 patients. The material was transpor ted 
to the laboratory of SE «Reference Centre for Molecu-
lar Diagnostics of the Ministry of Public Health (MPH) 
of Ukraine». For deparaffinization 750 µl of 100% xylol 
were added to paraffin tumor sections, they were treat-
ed in vortexer for 15 s and incubated at room tempera-
ture for 1 hour in thermoshaker. The samples were cen-
trifuged for 1 min at 12,000 g, supernatant was removed. 
Deparaffinization procedure was repeated for one time 
more. To remove the xylol remains after deparaffiniza-
tion the samples were washed in four steps. At the first 
step 1 ml of 100% ethanol was added to the material, af-
ter that the samples were treated in vortexer for 10 s, de-
fecated for 5 min at room temperature in thermoshaker 
and supernatant was removed. The first step was repeated 
for one time more. Second and third steps corresponded 
to the first step, beside the fact that 1 ml of 95% etha nol 
and 1 ml of 75% ethanol, respectively, were added to the 
samples. At final step the samples were washed in 1 ml of 
ddiH2O, treated in vortexer for 10 s, incubated for 5 min 
in thermoshaker and centrifuged for 1 min at 12,000, af-
ter that supernatant was removed.
DNA isolation from histological material was car-
ried out with commercial test-system «Quick-DNATM 
Universal Kit» (Zymo Research, USA) according to in-
structions for the kit. Into 1.5 µl centrifuge tube with 
the material which was purified from paraffin and xylol 
45 µl of ddiH2O, 45 µl of Solid Tissue Buffer and 10 µl 
of Proteinase K were added. The material was incuba-
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ted for 12 hours at 55 °С, periodically treated in vortex-
er for 10–15 s. After incubation the tubes were kept at 
94 °С for 20 min. Then 600 µl of Genomic Binding Buf-
fer was added to the samples and the material was treat-
ed with vortexer for 10–15 s, after that the samples were 
centrifuged at 12,000 g for 1 min. Supernatant was trans-
ferred to the column Zymo-SpinTM IIC-XL that was situat-
ed in collector tube and centrifuged for 1 min at 12,000 g. 
Then 400 µl of DNA Pre-Wash Buffer was added to the 
column with new collector tube, it was centrifuged for 
1 min at 12,000 g and the liquid was removed from the 
collector tube. Then 700 µl of g-DNA Wash Buffer was 
applied to the column and the sample was centrifuged 
1 min at 12,000 g, the liquid after centrifugation was re-
moved from the collector tube. One more time 200 µl 
of g-DNA Wash Buffer was applied to the column and 
the sample was centrifuged at 14,000 g for 1 min. The 
co lumn was transferred to clean microtube and 60 µl of 
DNA Elution Buffer was applied directly to column fil-
ter, after that the sample was incubated for 5 min at room 
temperature. The columns, inserted to centrifuge mic-
totubes, were centrifuged for 1 min at 14,000 g for DNA 
elution. The supernatant, containing purified DNA, was 
used for polymerase chain reaction (PCR).
Molecular-genetic study of polymorphous variants of 
ESR gene (A-351G, T-397C) was carried out in periphe-
ral blood samples of 44 patient with BC (n = 21) and 
OC (n = 23). Also molecular-genetic study of peripheral 
blood for the same polymorphisms occurrence was pro-
vided in 55 practically healthy females from control group 
that, according to family trees data, did not have here-
ditary risk factors of malignant pathology development.
Peripheral blood collection was provided into 2.5 ml 
sterile tubes of closed system «Monovette» with ethyle-
nediamine tetraacetate (EDTA) manufactured by the 
company «Sarstedt». Sterile tubes with collected mate-
rial were stored at −20 °С (not more than 1 month) in 
refrigerating chamber before transportation to State Es-
tablishment «Reference Centre for Molecular Diagnos-
tics of the MPH of Ukraine» (Kyiv). Samples transpor-
tation was performed in frozen state in cold containers. 
For DNA isolation from peripheral blood commercial 
kit «DNA-sorb-B» was applied (according to manu-
facturer’s instruction). Determination of studied genes 
polymorphism was provided using PCR with reagents of 
the company Thermo Scientific, for PCR performance 
modi fied protocol with appropriate primers was applied. 
The state of obtained amplification fragment was ana-
lyzed with electrophoresis in 2% agarose gel. Amplicons 
were subjected to hydrolytic degradation by restriction 
endonucleases, obtained fragments were analyzed with 
the method of restriction fragment length polymorphism 
(RFLP). Restriction was carried out in microthermostat 
at a temperature 37 °С for 12 hours. Restriction of poly-
morphous variants of ESR1 gene was terminated by heat-
ing at a temperature 65 °С for 20 min. The obtained frag-
ments were analyzed with electrophoresis in 2% agarose 
gel with addition of ethidium bromide and further visu-
alization by computer system Vitran.
Statistical processing was carried out with programs 
MS Excel 2010 and Statistica 10. To analyze the dif-
ferences of obtained numerical indices variation sta-
tistics me thods were used, and for genotypes frequen-
cy — Pearson’s criterion χ2 was applied, for less then 
ten samples Yate’s correction was applied and odds 
ratio (OR) was calculated with confidence interval 
(CI; 95% CI).
RESULTS AND DISCUSSION
Among the total number of examined females (n = 
90) the number of patients with OC (n = 23/25.6%) and 
BC (n = 21/23.3%) was almost the same, and the num-
ber of patients with PMT pathology was 46/51.1% (Ta-
ble 1). Age of patients with FRSO cancer from families 
with cancer family history was in the same range — from 
21 to 75 years (Table 2). The values of average age and 
median for decade did not have significant differences 
in the groups of examined females (р > 0.05).
Table 1
Distribution and characteristics of FRSO tumors in examined 
female patients (n = 90) with cancer family history
Pathology
Number of female 
patients examined, 
n (%)
(n = 90)
OC 23 (25.6)
BC 21 (23.3)
PMT (combination of malignant tumors of FRSO 
and gastro-intestinal tract) 46 (51.1)
Table 2
Distribution of probands (patients with FRSO cancer from families 
with cancer family history and healthy females without cancer 
cases in their family trees — control group) by average age and age 
median
Probands Average age and median, years21–30 31–40 41–50 51–60 51–70 >70
Patients with FRSO cancer from families with cancer positive family his-
tory, n = 90
Average age 28.6 36.5 46.5 54.7 64 73
Age median 29 33 41 53 65 72
Healthy females without cancer cases in their family trees, n = 55
(control group)
Average age 27.7 35.6 46.6 56.0 − −
Age median 29 39 48 52 − −
Reproductive-menstrual status of examined patients 
with FRSO cancer and females of control group is pre-
sented in the Table 3.
As can be seen from the Table 3, in patients, com-
paring with healthy females, significantly more fre-
quently (р < 0.05) menarche was observed in earli-
er age, and also they had greater number of deliveries 
and miscarriages. In 20% of cancer patients lactation 
was absent, there were two times more patients with 
menstrual duration 3 days, at that in 23.3% of patients 
their menstrual cycle was irregular, 37.8% of patients 
had in their anamnesis surgeries for benign processes 
in breast and uterine appendages, whereas healthy fe-
males did not have any surgical interventions in FRSO 
in anamnesis. The tumors in patients were diagnosed 
at prophylactic examinations (26.7%), by oncologist 
(44.4%), while in 28.0% of females FRSO tumors were 
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self-reported that indicated insufficient outreach to 
the public regarding early diagnosis of cancer and rel-
atives ignorance as to the existence of cancer patients 
in their families. The above dictates the need for clin-
ical-genealogical analysis of family pedigrees at pri-
mary examination of patients by oncogynecologist or 
another specialists.
The analysis of clinical-genealogical data in pedigrees 
of cancer patients has revealed a wide range of tumor pa-
thology — 321 tumors of different genesis, among them 
CC prevailed (31.5%). BC incidence was 23.0%, uter-
ine body cancer — 21.2%, OC — 18.1%, in other words, 
incidence of tumors of hormone-dependent organs was 
rather large and comprised 62.3%. GC demonstrated 
the lowest rate among all the tumors (6.2%) (Table 4).
Table 4
Tumors distribution in family trees of probands  
(considering proband’s tumors)
Malignant tumors Number of tumors,n (%)
Endometrial cancer (EC) 68 (21.2)
OC 58 (18.1)
BC 74 (23.0)
CC 101 (31.5)
GC 20 (6.2)
Total 321 (100)
Therefore, resulting from clinical-genealogical 
exami nation of patients, tumors association in fami-
ly trees in the form of family cancer syndrome was de-
termined that was also demonstrated by probands’ pe-
digrees (Fig. 1–4).
Fig. 1. Pedigree of proband Ch.I.V., 29 years (observation 
No. 53). Family cancer syndrome. Proband has BC stage I. 
In I generation of pedigree — tree patients with BC in the age 
of 52; 62; 65 years, CC (72 years), EC — (62 years), GC (65 
years). The results of proband’s molecular-genetic examina-
tion: SNP of the gene ERS1 (AC, AG,), genes BRCA 1/2 (−)
Legend: yr — years
Table 3
Reproductive-menstrual status of examined patients with FRSO cancer and females of control group
Characteristics
Patients with  
FRSO cancer, n (%)
(n = 90)
Healthy females  
(control group), n (%)
(n = 55)
Onset of menarche Before age of 12
90
20 (22.2)
55
3 (5.5)
12–15 years 57 (63.3) 45 (81.8)
Older than 15 years 13 (14.5) 7 (12.7)
Number of deliveries 0
90
3 (3.3)
55
11 (20.0)
1–2 deliveries 59 (65.5) 40 (72.7)
More than 3 28 (31.1) 4 (7.3)
Number of abortions 0
90
54 (60.0) 55 35 (63.6)
1–2 30 (33.3) 15 (27.3)
More than 3 6 (6.7) 5 (9.1)
Number of miscarriages 0
90
74 (82.2)
55
0
1–2 10 (11.1) 0
More than 3 6 (6.7) 0
Lactation Was absent
Lactation:
till 6 months
6–12 months
> 1 year
18
72
18 (20.0)
30 (41.7)
26 (36.1)
16 (22.2)
0
44
0
8 (18.2)
14 (31.8)
22 (50.0)
Number of menstrual
days
Up to 3 days
90
19 (21.1)
55
6 (10.9)
4–6 days 58 (64.4) 42 (76.4)
7 days and more 13 (14.5) 7 (12.7)
Menstrual
duration
Regular
(24–32 days) 90 69 (76.7) 55 53 (96.3)
Irregular (more
than 32 days) 21 (23.3) 2 (3.6)
Menopause
duration
Up to 5 years
36
10 (27.8)
15
5 (33.3)
5–10 years 10 (27.8) 5 (33.3)
More than 10 years 16 (44.4) 5 (33.3)
FRSO
surgeries in anamnesis
Were absent
90
56 (62.2)
55
0
In uterine appendages 9 (10.0) 0
In breasts 25 (27.8) 0
Tumor
diagnostics
At prophylactic
examination 90 24 (26.7) 55 0
Self-reported 26 (28.9) 0
By oncologist 40 (44.4) 0
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Fig. 2. Pedigree of proband G.S.N., 53 years (observation 
No. 58). Family cancer syndrome. Proband has BC stage I. 
In her mother — BC (52 years), in her father — GC (69 years), 
and patient with CC (65 years), and patient (69 years) — GC. 
The results of proband’s molecular-genetic examination: SNP 
of the gene ERS1 (СC, GG), genes BRCA 1/2 (−)
Legend: yr — years
Fig. 3. Pedigree of proband Т.І.V., 29 years (observation No. 78). 
Family cancer syndrome. Proband has OC. In her pedigree — 
aggregation of malignant tumors: two patients with hepar can-
cer (56 and 62 years), prostate cancer (53 years), CC (48 years). 
The results of proband’s molecular-genetic examination: SNP 
of the gene ERS1 (АG), gene BRCA 1 (−) 
Legend: PC — prostate cancer; HC — hepar cancer; yr — years
Fig. 4. Pedigree of proband S.G.V., 36 years (observation No. 13).
Proband has primary-multiple cancer — EC (adenocarcinoma) 
and cancer colli uteri (squamous cell carcinoma). Family can-
cer syndrome. In her mother — ОС (72 years), in father — GC 
(55 years). In I and II generations — CC in 68 and 55 years. The 
results of proband’s molecular-genetic examination: SNP of the 
gene ERS1 (СС, GG), gene BRCA 1/2 (−) 
Legend: CCU — cancer colli uteri; yr — years
Molecular-genetic examination comprised the de-
tection of products of restriction analysis of gene ESR1 
fragment in BC and OC tumors which results are pre-
sented in the Fig. 5 and 6.
ESR1 A-351G
Fig. 5. Electrophoregram of restriction analysis products of 
ESR1 gene fragment (A-351G). Samples: 1, 8, 10 — genotype 
АG; 2, 4, 6, 7, 9 — genotype AА; 3, 5 — genotype GG; 11 — 
molecular weight marker
ESR1 T-397C
Fig. 6. Electrophoregram of restriction analysis products of 
ESR1 gene fragment (T-397C). Samples: 1, 3, 4, 6, 9 — geno-
type TC; 2 — genotype CC; 5, 7, 8, 10 — genotype TT; 11 — 
molecular weight marker
Basing on the results of molecular-genetic tumors 
examination different genotypes frequency of the gene 
ESR1 in examined cancer patients comparing with ex-
amination results of healthy females was determined (Ta-
ble 5). According to the results of statistical processing of 
the results in cancer patients the frequency of genotype 
ТТ of the gene ESR1 (T-397C) was lower comparing with 
control data and comprised 25.56% versus 61.82% (р = 
0.001). In contrast, the frequency of genotypes ТС and 
СС of the same polymorphous variant of the gene ESR1 
(T-397C) was significantly higher and comprised 52.22% 
versus 32.73% (p = 0,034) and 22.22% versus 5.45%, re-
spectively (р = 0.014).
The frequency of genotypes АА, AG, GG of the gene 
ESR1 (A-351G) also was different in cancer patients com-
paring with these indices in healthy females: significant 
reduction of genotype АА frequency up to 33.33% ver-
sus 67.27% in healthy females (p = 0.001), significant in-
crease of genotype AG frequency from 32.73 to 57.78% 
(p = 0.006), tendency to increase of genotype GG fre-
quency — from zero to 8.89% (p = 0.057).
The largest relative risk of cancer development 
(OR = 4.95) at 95% CI was determined for genotype СС 
of polymorphous variant T-397C of the gene ESR1, two 
times lower relative risk (OR = 2.5) at 95% CI for geno-
type ТС, the lowest relative risk (OR = 0.21) at 95% CI 
for genotype ТТ of the same gene. Considering polymor-
phous variant A-351G of the gene ESR1, the largest risk 
of cancer development (OR at 95% СІ is 2.81) is possi-
ble at genotype АG of polymorphous variant A-351G 
of the gene ESR1, and a minor risk (0.24) at genotype 
АA of polymorphous variant A-351G of the gene ESR1.
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Therefore, the data presented suggest the variabili-
ty of the risk of oncologic pathology development de-
pending on genotypes of polymorphous variants T-
397C and A-351G of the gene ESR1. The largest risk of 
cancer deve lopment in females with family cancer syn-
drome in family was determined in case of genotype СС 
of polymorphous variant of the gene ESR1 (T-397C), 
and 2.2 times lesser risk at genotype TC of the same 
polymorphous gene variant. In case of polymorphous 
variant of the gene ESR1 (A-351G) the largest risk was 
found at genotype АG.
During analysis of variability of genotypes frequen-
cies a number of issues emerged: what was a frequency 
of determined polymorphous variants of the gene ESR1 
(Т-397С, A-351G) in patients from families with cancer 
family history and in practically healthy females, what 
was a frequency of polymorphous variants of the gene 
ESR1 depending on tumors genesis — in patients with 
OC and BC, what was genetic risk of cancer develop-
ment in families with aggregation of tumor pathology. 
As it can be seen from the Table 6, in patients with FRSO 
polymorphous variants of the gene ESR1 (A-351G) are 
determined with almost similar frequency — 57.8% of 
patients, comparing with polymorphous variants of the 
gene ESR1 (T-397C) — 52.2% (p > 0.05). Healthy fe-
males do not have differences between the same poly-
morphous variants at all, 32.7%, respectively. In con-
trast, in healthy females more frequently (р < 0.05) gen-
otype 397TT (61.8%) of polymorphous variant of the 
gene ESR1 (T-397С) and genotype 351AA (67.3%) of 
polymorphous variant of the gene ESR1 (A-351G) are 
determined, comparing with its frequency in cancer pa-
tients: 25.6 and 33.3%, respectively.
Therefore, provided complex examination deter-
mined the frequency of SNP of receptor gene ESR1 and 
assessed the risk of malignant pathology development 
in families of probands with family cancer syndrome. 
The obtained data indicate individual genotypes alte-
rations that may be associated both with tumor genesis 
and with genetic mutation in families that are passed by 
family members from generation to generation. The ob-
tained data complement and deepen the data of our pre-
vious clinical-genealogical examinations and molecular-
genetic studies of peripheral blood of females with FRSO 
cancer [20]. In Western region of Ukraine (Lviv region) 
at clinical-genetic females examination the authors found 
mutations in BRCA1/2 genes in patients with family/he-
reditary BC [21]. We determined that in predisposition 
of females of Ukrainian population to FRSO cancer de-
velopment, in particular, to family/hereditary BC deve-
lopment, not only mutations in genes-suppressors of tu-
mor growth BRCA1 and BRCA2 play the role, but also 
mutations in the gene ESR1 are involved.
The mechanisms of malignant transformation of so-
matic cells and predisposition to cancer development — 
are the most actual issues of oncology. It is known that 
proliferation of the cells of hormone-dependent organs 
is estrogen-regulated. Disorders of hormones’ physiolo-
gical influence on cells of breast, ovaries and uterus may 
occur resulting from alterations of hormones levels or 
disorder of balance between hormone fractions, or due 
to the damage of molecular structure of receptor gene 
ERS1. The latter can be caused by mutations, in partic-
ular, by single nucleotide substitutions (SNP) in a gene 
that in turn contributes to disruption of normal pathway 
of gene ERS1 activation.
Table 5
The frequency of genotypes of polymorphous variants of the gene ESR1 (Т-397С, A-351G)
Gene ESR1
Polymorphous variant T-397C Cancer (n = 90) Control (n = 55) Statistical analysis results
Genotypes n % n % χ² p OR 95% CI
ТТ 23 25.56 34 61.82 17.33 0.001 0.21 0.10–0.44
TC 47 52.22 18 32.73 4.49 0.034 2.25 1.12–4.52
СС 20 22.22 3 5.45 5.99 0.014 4.95 1.40–17.55
Gene ESR1
Polymorphous variant A-351G Cancer (n =90) Control (n = 55) Statistical analysis results
Genotypes n % n % χ² p OR 95% CI
AA 30 33.33 37 67.27 14.48 0.001 0.24 0.12–0.50
AG 52 57.78 18 32.73 7.61 0.006 2.81 1.39–5.67
GG 8 8.89 0 0.00 3.61 0.057 −* −
*OR was not calculated due to absence of genotype GG in control.
Table 6
The differences in frequencies of genotypes occurrence of polymorphous variants T-397C, A-351G of the gene ESR1 in comparison 
groups — patients with FRSO cancer from families with cancer family history and healthy females
Probands examined,
n/%
Genotype of polymorphous variant  
T-397C and number of patients, n (%)
Genotype of polymorphous variant  
A-351G and number of patients, n (%)
397TT 397TC 397CC 351AA 351AG 351GG
EC (23/100%) 3 (13.0) 10 (43.5) 10 (43.5) 11 (47.8) 10 (43.5) 2 (8.7)
BC (21/100%) 3 (14.3) 13 (61.9) 5 (23.8) 4 (19.1) 15 (71.4) 2 (9.5)
Uterine body cancer (46/100%) 17 (36.9) 24 (52.2) 5 (10.9) 15 (32.6) 27 (58.7) 4 (8.7)
TOTAL number of FRSO cancer patients,  
n = 90/100%
23
(25.6)
47
(52.2)
20
(22.2)
30
(33.3)
52
(57.8)
8
(8.9)
Control group — healthy females, n = 55/100% 34
(61.8)
18
(32.7)
3
(5.5)
37
(67.3)
18
(32.7) −
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In recent years, the role of SNP in cell malignization 
has been widely studied and actively discussed. As causal 
factors of BC 16 candidate SNPs and 13 genes were de-
termined. Among the latter significant attention is paid 
to gene MBIP (MAP3K12-binding inhibitory protein 1) 
that regulates activity of cycline-dependent kinases and 
gene RPS6KA that participates in control of growth and 
cell differentiation. The gene MBIP product functions as 
membrane receptor that is involved in different physio-
logical and pathological processes (in embryogenesis, ho-
meostasis, reparation, immune response and tumor cells 
metastasing). Also several signal pathways of regulation 
of the gene PTEN that makes a definite contribution to 
predisposition to BC development were determined; its 
expression reduction is associated with worse BC prog-
nosis [22, 23]. The above is a convincing evidence of the 
cardinal role of genetic alterations in cancer pathogene-
sis that does not diminish the importance of epigenetic 
changes that occur under the influence of intrinsic fac-
tors of the organism, influencing on particularities of its 
development and causing age-dependent diseases [24].
Obviously, for tumor development associations of 
multiple genes polymorphisms and epigenetic changes 
are of importance. It was determined that in such cases 
only one third of associations was statistically linked to 
genes, coding cellular metabolism [25]. Through meta-
analysis significant associations of other genes polymor-
phism with neoplasias risk were identified. The majori-
ty of researchers from different countries consider muta-
tion of one gene allele as a genetic factor of predisposition 
to BC — heterozygous clones with gene BRCF1/2 mu-
tation lead to genomic instability that may be genetic 
background for cells malignization, and mutation in two 
gene alleles — the reason of tumor genesis [26, 27]. Some 
authors [28–30] during exploration of germinal muta-
tions in genes concluded that gene polymorphism acted 
as a genetic modifier of prognosis (better or worse). Ac-
cording to some authors [30] genomic instability — is a 
«hallmark of cancer», leading to genetic alterations aug-
mentation, tumor genesis and tumor progression. Dif-
ferent types of genetic instability (nucleotide, microsa-
tellite, and chromosome) occur both in individual chara-
cteristics, and through different tumors. According to the 
data of investigation of numerous genomic associations 
(GWASs) and meta-analysis data [4] there is a wide range 
of polymorphous gene variants in cancer patients, and 
only 31.7% of genes of 145 polymorphous gene variants 
were associated with BC. Studies on relation of gene mu-
tations to receptor status of breast cells will be interes ting. 
It was demonstrated that, depending on BC receptor sta-
tus, different mutations of the genes BRCA1/2 are deter-
mined: increased frequency of C homozygotes in patients 
with estrogen-negative tumors, whereas in other situa-
tion (positive estrogen and progesterone receptor status) 
other mutations were observed.
In general, the knowledge of occurrence of polymor-
phous variants of receptor gene ESR1, associated with in-
crease of neoplasias risk, is extremely important at medi-
cal-genetic counseling and examination of females, in 
particular, in females from families with cancer fami-
ly history for determination of potential risk of neopla-
sias development. Adequate prognosis for the develop-
ment of FRSO cancer and OC in females with tumor 
pathology in several generations of their family trees is 
impossible without knowledge of family cancer history 
and studies of polymorphism of estrogen gene ERS1 in 
such females. Provided studies and their continuation is 
an important first step and one of predictive genomics 
approaches. In terms of research performed — this is a 
determination of individual genetic alterations in tumor 
cells and individu al risk of malignization development in 
persons, having cancer patients in their pedigrees.
Our results open the perspective of novel strategy for 
further studies of the problem of early diagnostics and 
prevention of FRSO malignant tumors. Its focus lies 
not only in identifying families with aggregation of ma-
lignant tumors in their pedigrees, but also in identifica-
tion of carriers of mutations of genes-suppressors BRCA1 
and BRCA2 and SNP of receptor gene ESR1 in families 
with family cancer syndrome or PMT. Establishment of 
clinical-genetic register of such persons within certain 
regions of Ukraine to address issues concerning mon-
itoring of their health, prophylaxis and pre-clinical di-
agnostics of hereditary forms of FRSO cancer and oth-
er tumors within the frame of family cancer syndrome is 
one of the actual tasks of clinical oncology.
CONCLUSIONS
1. Clinical-genealogical examination of patients 
with BC, OC determined wide range of tumor patholo-
gy; most of them were patients with CC (31.5%). Total 
number of cancers of hormone-dependent organs (uter-
ine body cancer, BC, OC) was 62.3%. Tumors associ-
ation in family trees corresponds to family cancer syn-
drome (Lynch II syndrome).
2. In patients the frequency of genotype ТТ of poly-
morphous variant of the gene ESR1 (T-397C) was signi-
ficantly lower than in control and comprised 25.56% ver-
sus 61.82%. In contrast, the frequency of genotypes ТС 
(52.22%) and СС (22.22%) of the same polymorphous 
variant of the gene ESR1 was significantly higher compar-
ing with control data — 32.73% and 5.45%, respectively.
3. The frequency of genotypes АА, AG, GG of the 
gene ESR1 (A-351G) also was different in cancer patients 
comparing with these values in healthy females: signi-
ficant reduction of genotype АА frequency to 33.33% 
versus 67.27% in healthy females, significant increase 
of genotype АD frequency from 32.73% to 57.78%, ten-
dency to increase of genotype GG frequency — from 
zero to 8.89%.
4.In patients with FRSO cancer significant chan-
ges in the frequency of polymorphous variants of the 
gene ESR1 (A-351G) were not found — (57.8% of pa-
tients) and polymorphous variants of the gene ESR1 (T-
397C) — (52.2% of patients). In healthy females the 
difference between the same polymorphous variants of 
the gene ESR1 also was not seen (32.7%, respectively). 
In contrast, in healthy females genotype 397TT (61.8%) 
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of polymorphous variant of the gene ESR1 (T-397С) and 
genotype 351AA (67.3%) of polymorphous variant of 
the gene ESR1 (A-351G) was detected more frequently 
(р < 0.05) comparing with their frequency in cancer pa-
tients: 25.6 and 33.3%, respectively.
5. The risk of tumor development (OR; 95% CІ) in 
probands’ families with cancer aggregation depends on 
polymorphous variant of the gene ESR1. The highest OR 
is 4.95 (1.40–17.55) at genotype СС of polymorphous 
variant of the gene ESR1 (T-397C), whereas at genotype 
TC of the same polymorphous variant of the gene it re-
duces to 2.25 (1.12–4.52). OR for 95% CІ at polymor-
phous variant of the gene ESR1 (A-351G) is lower and it 
comprises 2.81 (1.39–5.67). For genotype 351АА of the 
same gene protective effect was estimated.
6. The obtained results suggest the need for clini-
cal-genealogical and molecular-biological studies in 
patients with FRSO cancer with burdened family his-
tory of malignant pathology for formation of genetic 
risk groups and monitoring of females health, for can-
cer prevention by treatment of pre-cancerous and in-
flammatory FRSO processes. Determination of SNPs of 
estrogen receptor gene ESR1 as genetic markers of pre-
disposition to malignant tumors development is a basis 
for their application at development of clinical proto-
cols of examination of members of families with fami-
ly cancer syndrome for determination of individual risk 
of neoplasias development.
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КЛІНІЧНЕ ЗНАЧЕННЯ МУТАЦІЙ (SNP) 
ГЕНА РЕЦЕПТОРА ЕСТРОГЕНА ERS1 
У ХВОРИХ НА РАК З ОНКОЛОГІЧНОЮ 
ПАТОЛОГІЄЮ У РОДОВОДАХ
О.В. Палійчук, Л.З. Поліщук,  
З.І. Россоха, В.Ф. Чехун
Резюме. Стаття присвячена визначенню генетич-
ного ризику виникнення онкологічної патології у ро-
динах пробандів із сімейною історією раку (про-
банди — хворі на рак молочної залози, рак яєчника, 
первинно-множинні пухлини) шляхом оцінки резуль-
татів клініко-генеалогічного обстеження хворих 
та генетичного аналізу мутацій (SNP — однону-
клеотидний поліморфізм) гена рецептора естроге-
на ERS1. Методи дослідження: клінічний, морфоло-
гічний, клініко-генеалогічний, молекулярно-генетич-
ний, статистичний. Результати: серед обстежених 
було 90 хворих на рак і 55 здорових жінок без випад-
ків раку у родоводах (група контролю). Встановле-
но, що асоціація злоякісних пухлин у родоводах хво-
рих жінок відповідала сімейному раковому синдрому 
(синдром Лінча II типу). При молекулярно-генетич-
ному дослідженні геномної ДНК периферичної крові 
та гістологічного матеріалу пухлин визначено до-
стовірне підвищення частоти генотипу 397СС гена 
ESR1 у хворих на рак з агрегацією злоякісної пато-
логії у родинах порівняно з частотою цього геноти-
пу у жінок із групи контролю. Статистичний ана-
ліз показав, що ризик розвитку злоякісної патології 
(відношення шансів — ВШ; 95% довірчий інтервал — 
ДІ) підвищується у 4,95 раза у випадках СС гено-
типу гена ESR1 (T-397C), а у разі гетероносійства 
цього гена — у 2,25 раза. За наявності ТТ генотипу 
гена ESR1 (T-397C) ризик розвитку раку знижуєть-
ся (ВШ 0,21). Висновок: частота генотипів АА, AG, 
GG гена ESR1 (A-351G) також відрізняється у хво-
рих на рак порівняно зі здоровими жінками: значне 
зниження частоти АА генотипу до 33,33% порів-
няно з 67,27% у здорових жінок (p = 0,001), значне 
підвищення частоти AG генотипу із 32,73 до 57,78% 
(p = 0,006), тенденція до зростання частоти GG ге-
нотипу — від 0 до 8,89% (p = 0,057). Одержані ре-
зультати є основою для проведення клініко-генеа-
логічних та молекулярно-генетичних досліджень 
у родинах з агрегацією раку органів жіночої репро-
дуктивної системи для детекції SNP гена ESR1. Ви-
явлений SNP поліморфізм вказаного гена може бути 
предиктором розвитку раку та агрегації злоякісних 
пухлин у родинах пробандів та їх нащадків.
Ключові слова: пухлини органів жіночої 
репродуктивної системи, родовід, сімейний 
раковий синдром, однонуклеотидний 
поліморфізм гена ESR1.
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